Terms: = Prostate cancer AND NBN, AT-V2, 4683, ENSG00000104320, ATV, FLJ10155, NBS, AT-V1, MGC87362, NBS1 AND Treatment
34 results:
1. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive prostate cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract] [Full Text] [Related]
2.
Ma XK; Liu TL; Ren YN; Ma XP; Yao Y; Hou XG; Ding J; Wang F; Huang HF; Zhu H; Yang Z
Acta Pharmacol Sin; 2024 Feb; 45(2):436-448. PubMed ID: 37749238
[TBL] [Abstract] [Full Text] [Related]
3. Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients.
Paulo P; Cardoso M; Brandão A; Pinto P; Falconi A; Pinheiro M; Cerveira N; Silva R; Santos C; Pinto C; Peixoto A; Maia S; Teixeira MR
Genes Chromosomes Cancer; 2023 Dec; 62(12):710-720. PubMed ID: 37436117
[TBL] [Abstract] [Full Text] [Related]
4. Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with Prognosis of prostate cancer Patients.
Lieb V; Abdulrahman A; Weigelt K; Hauch S; Gombert M; Guzman J; Bellut L; Goebell PJ; Stöhr R; Hartmann A; Wullich B; Taubert H; Wach S
Cells; 2022 Nov; 11(22):. PubMed ID: 36429046
[TBL] [Abstract] [Full Text] [Related]
5. Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
Satapathy S; Das CK; Aggarwal P; Sood A; Parihar AS; Singh SK; Mittal BR
Prostate; 2023 Feb; 83(2):169-178. PubMed ID: 36259290
[TBL] [Abstract] [Full Text] [Related]
6. Molecular Profile Changes in Patients with Castrate-Resistant prostate cancer Pre- and Post-Abiraterone/Prednisone treatment.
Sicotte H; Kalari KR; Qin S; Dehm SM; Bhargava V; Gormley M; Tan W; Sinnwell JP; Hillman DW; Li Y; Vedell PT; Carlson RE; Bryce AH; Jimenez RE; Weinshilboum RM; Kohli M; Wang L
Mol Cancer Res; 2022 Dec; 20(12):1739-1750. PubMed ID: 36135372
[TBL] [Abstract] [Full Text] [Related]
7. Germline genetics of prostate cancer.
Khan HM; Cheng HH
Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S3-S12. PubMed ID: 35657157
[TBL] [Abstract] [Full Text] [Related]
8. Clinical Significance of Gene Mutations and Polymorphic Variants and their Association with prostate cancer Risk in Polish Men.
Heise M; Jarzemski P; Nowak D; Bąk A; Junkiert-Czarnecka A; Pilarska-Deltow M; Borysiak M; Pilarska B; Haus O
Cancer Control; 2022; 29():10732748211062342. PubMed ID: 35638715
[No Abstract] [Full Text] [Related]
9. Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded prostate cancer Index Composite for Clinical Practice in Spain.
Zapatero A; Maldonado Pijoan X; Gómez-Caamaño A; Pardo Masferrer J; Macías Hernández V; Hervás Morón A; Muñoz García JL; Palacios Eito A; Anguita-Alonso P; González-Junco C; López Torrecilla J
Health Qual Life Outcomes; 2021 Sep; 19(1):223. PubMed ID: 34563208
[TBL] [Abstract] [Full Text] [Related]
10. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract] [Full Text] [Related]
11. Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA.
Wang Y; De Leon AC; Perera R; Abenojar E; Gopalakrishnan R; Basilion JP; Wang X; Exner AA
Sci Rep; 2021 Feb; 11(1):4726. PubMed ID: 33633232
[TBL] [Abstract] [Full Text] [Related]
12. Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN.
Hirama H; Sugimoto M; Miyatake N; Kato T; Venderbos LDF; Remmers S; Shiga K; Yokomizo A; Mitsuzuka K; Matsumoto R; Osawa T; Abe T; Sasaki H; Egawa S; Ninomiya I; Hashine K; Roobol MJ; Kakehi Y
World J Urol; 2021 Jul; 39(7):2491-2497. PubMed ID: 33079252
[TBL] [Abstract] [Full Text] [Related]
13. Evaluation of a Mainstream Model of Genetic Testing for Men With prostate cancer.
Scheinberg T; Goodwin A; Ip E; Linton A; Mak B; Smith DP; Stockler MR; Strach MC; Tran B; Young AL; Zhang AY; Mahon KL; Horvath LG
JCO Oncol Pract; 2021 Feb; 17(2):e204-e216. PubMed ID: 32970524
[TBL] [Abstract] [Full Text] [Related]
14. Multifunctional nanobubbles carrying indocyanine green and paclitaxel for molecular imaging and the treatment of prostate cancer.
Lan M; Zhu L; Wang Y; Shen D; Fang K; Liu Y; Peng Y; Qiao B; Guo Y
J Nanobiotechnology; 2020 Sep; 18(1):121. PubMed ID: 32883330
[TBL] [Abstract] [Full Text] [Related]
15. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
16. Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes.
Kratochwil C; Giesel FL; Heussel CP; Kazdal D; Endris V; Nientiedt C; Bruchertseifer F; Kippenberger M; Rathke H; Leichsenring J; Hohenfellner M; Morgenstern A; Haberkorn U; Duensing S; Stenzinger A
J Nucl Med; 2020 May; 61(5):683-688. PubMed ID: 31601699
[TBL] [Abstract] [Full Text] [Related]
17. Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review.
Swift SL; Lang SH; White H; Misso K; Kleijnen J; Quek RG
Future Oncol; 2019 Oct; 15(28):3283-3303. PubMed ID: 31535940
[TBL] [Abstract] [Full Text] [Related]
18. Germline DNA Repair Gene Mutations in Young-onset prostate cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.
Leongamornlert DA; Saunders EJ; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Benafif S; Brook MN; Donovan JL; Hamdy FC; Neal DE; Muir K; Govindasami K; Conti DV; Kote-Jarai Z; Eeles RA
Eur Urol; 2019 Sep; 76(3):329-337. PubMed ID: 30777372
[TBL] [Abstract] [Full Text] [Related]
19. DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.
Lotan TL; Kaur HB; Alharbi AM; Pritchard CC; Epstein JI
Histopathology; 2019 May; 74(6):836-843. PubMed ID: 30636012
[TBL] [Abstract] [Full Text] [Related]
20. Transition zone and anterior stromal prostate cancers: Evaluation of discriminant location criteria using multiparametric fusion-guided biopsy.
Tavolaro S; Mozer P; Roupret M; Comperat E; Rozet F; Barret E; Drouin S; Vaessen C; Lucidarme O; Cussenot O; Boudghène F; Renard-Penna R
Diagn Interv Imaging; 2018 Jun; 99(6):403-411. PubMed ID: 29477489
[TBL] [Abstract] [Full Text] [Related]
[Next]
